Tramadol News and Research

RSS

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Cipher Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults.

10 May 2010

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail Corporation today announced its financial results for the three-month period ended March 31, 2010.

6 May 2010

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm Inc. today reported its financial results for the first quarter 2010.

6 May 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical Companies, Inc. today reported results for the first quarter ended March 31, 2010.

4 May 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2010.

23 Apr 2010

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

21 Apr 2010

Labopharm: Investment report

StockPreacher.com announces an investment report featuring Labopharm Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Labopharm Inc. today announced its wholly owned subsidiary, Labopharm Europe Limited, has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku Co., Ltd. of Japan.

8 Apr 2010

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Cipher Pharmaceuticals Inc. today announced that it has reached the enrollment mid-point in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. To date, more than 400 patients have been enrolled. Achieving this milestone triggers a US$2.0 million milestone payment from Ranbaxy Pharmaceuticals Inc., Cipher's U.S. marketing and distribution partner.

1 Apr 2010

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Labopharm Inc. today reported its financial results for the fourth quarter and fiscal year ended December 31, 2009. All figures are in Canadian dollars unless otherwise stated.

25 Feb 2010

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Par Pharmaceutical Companies, Inc. today reported results for the fourth quarter and full year ended December 31, 2009.

24 Feb 2010

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent, according to surveyed European neurologists.

24 Feb 2010

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm Inc. today announced that the underwriters for the recently announced public offering of newly issued units have exercised in full their over-allotment option to purchase an additional 1,764,706 units. The 1,764,706 additional units are being sold at the public offering price of US$1.70 per unit and will bring the total number of units issued under the public offering to 13,529,412 units.

20 Feb 2010

Labopharm closes previously announced underwritten public offering of 11,764,706 units

Labopharm Inc. today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.

19 Feb 2010

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009.

17 Feb 2010

Labopharm prices underwritten public offering of 11.7M units

Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.

15 Feb 2010

New pain management options for patients undergoing knee or hip replacements

Patients undergoing knee or hip replacements recover more quickly when treated with targeted pain-blocking medications that may eliminate the need for general anesthesia during surgery and intravenous narcotics drugs after surgery.

12 Feb 2010